Show simple item record

dc.contributor.authorAdams, JM
dc.contributor.authorCory, S
dc.date.accessioned2020-12-18T04:12:50Z
dc.date.available2020-12-18T04:12:50Z
dc.date.issued2018-01-01
dc.identifierpii: cdd2017161
dc.identifier.citationAdams, J. M. & Cory, S. (2018). The BCL-2 arbiters of apoptosis and their growing role as cancer targets. CELL DEATH AND DIFFERENTIATION, 25 (1), pp.27-36. https://doi.org/10.1038/cdd.2017.161.
dc.identifier.issn1350-9047
dc.identifier.urihttp://hdl.handle.net/11343/256099
dc.description.abstractImpaired apoptosis plays a central role in cancer development and limits the efficacy of conventional cytotoxic therapies. Deepening understanding of how opposing factions of the BCL-2 protein family switch on apoptosis and of their structures has driven development of a new class of cancer drugs that targets various pro-survival members by mimicking their natural inhibitors, the BH3-only proteins. These 'BH3 mimetic' drugs seem destined to become powerful new weapons in the arsenal against cancer. Successful clinical trials of venetoclax/ABT-199, a specific inhibitor of BCL-2, have led to its approval for a refractory form of chronic lymphocytic leukaemia and to scores of on-going trials for other malignancies. Furthermore, encouraging preclinical studies of BH3 mimetics that target other BCL-2 pro-survival members, particularly MCL-1, offer promise for cancers resistant to venetoclax. This review sketches the impact of the BCL-2 family on cancer development and therapy, describes how interactions of family members trigger apoptosis and discusses the potential of BH3 mimetic drugs to advance cancer therapy.
dc.languageEnglish
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleThe BCL-2 arbiters of apoptosis and their growing role as cancer targets
dc.typeJournal Article
dc.identifier.doi10.1038/cdd.2017.161
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.source.titleCell Death and Differentiation
melbourne.source.volume25
melbourne.source.issue1
melbourne.source.pages27-36
melbourne.identifier.nhmrc461221
dc.rights.licenseCC BY
melbourne.elementsid1312033
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729526
melbourne.contributor.authorAdams, Jerry
melbourne.contributor.authorCory, Suzanne
dc.identifier.eissn1476-5403
melbourne.identifier.fundernameidNHMRC, 461221
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record